-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

Benzinga·05/13/2026 21:14:11
Listen to the news
D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.